CA3024155C — Low dose oral formulations of seladelpar and use thereof in the treatment of primary biliary cholangitis.
Assigned to CymaBay Therapeutics Inc · Expires 2023-10-10 · 3y expired
What this patent protects
Low dose oral formulations of seladelpar or a salt thereof for the treatment of primary biliary cholangitis are disclosed. Specifically, the disclosure relates to a compound that is seladelpar or a salt thereof for use in the treatment of primary biliary cholangitis, the use of t…
USPTO Abstract
Low dose oral formulations of seladelpar or a salt thereof for the treatment of primary biliary cholangitis are disclosed. Specifically, the disclosure relates to a compound that is seladelpar or a salt thereof for use in the treatment of primary biliary cholangitis, the use of the compound for the treatment of primary biliary cholangitis, and the use of the compound for manufacturing a medicament for the treatment of primary biliary cholangitis, in each instance where the compound is formulated for oral administration at a dose of 5 mg/day or 10 mg/day when the dose is calculated as seladelpar.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.